-+ 0.00%
-+ 0.00%
-+ 0.00%

BTIG Reiterates Buy on Kazia Therapeutics, Maintains $40 Price Target

Benzinga·09/10/2026 13:13:39
Listen to the news
BTIG analyst Kambiz Yazdi reiterates Kazia Therapeutics (NASDAQ:KZIA) with a Buy and maintains $40 price target.